Journal of Aging Research [113] J. S. Wei, Y. K. Song, S. Durinck et al., “The MYCN oncogene is a direct target of miR-34a,” Oncogene, vol. 27, no. 39, pp. 5204–5213, 2008. [114] M. Yamakuchi, M. Ferlito, and C. J. Lowenstein, “miR-34a repression of SIRT1 regulates apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 36, pp. 13421–13426, 2008. [115] L. Aagaard and J. J. Rossi, “RNAi therapeutics: principles, prospects and challenges,” Advanced Drug Delivery Reviews, vol. 59, no. 2-3, pp. 75–86, 2007. [116] J. Kota, R. R. Chivukula, K. A. O’Donnell et al., “Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver Cancer Model,” Cell, vol. 137, no. 6, pp. 1005–1017, 2009. [117] T. V. Chirila, P. E. Rakoczy, K. L. Garrett, X. Lou, and I. J. Constable, “The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides,” Biomaterials, vol. 23, no. 2, pp. 321–342, 2002. [118] N. L. Rosi, D. A. Giljohann, C. S. Thaxton, A. K.R. Lytton- Jean, M. S. Han, and C. A. Mirkin, “Oligonucleotide- modiﬁed gold nanoparticles for infracellular gene regula- tion,” Science, vol. 312, no. 5776, pp. 1027–1030, 2006. [119] I. S. Zuhorn, J. B. F. N. Engberts, and D. Hoekstra, “Gene delivery by cationic lipid vectors: overcoming cellular barriers,” European Biophysics Journal, vol. 36, no. 4-5, pp. 349–362, 2007. 11